Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galera Therapeutics filings document a clinical-stage oncology company’s material agreements, governance matters, capital structure and operating disclosures. The company’s SEC reports include 8-K events for asset transactions involving dismutase mimetics, amendments to preferred-stock terms, conversions of Series B Non-Voting Convertible Preferred Stock, pre-funded warrant exercises, and executive compensation arrangements.
Galera’s proxy and annual-meeting materials cover stockholder voting procedures, director nominations, governance requirements and related capital-structure disclosures. Its public-company records also identify GRTX common stock on the OTCQB Market and provide formal disclosure of financial results, reporting obligations, risk-related matters and corporate actions affecting the company’s oncology development business.
Ikarian Capital, LLC and Neil Shahrestani filed Amendment No. 1 to a Schedule 13G regarding Galera Therapeutics, Inc. common stock. The amendment reports that the Reporting Persons now have beneficial ownership of 0.00 shares and 0% of the class, with no sole or shared voting or dispositive power over any Galera Therapeutics shares.
The filing explains that a fund and certain separately managed accounts advised by Ikarian Capital are the record owners of the securities previously covered, and details how investment discretion is exercised. Each party, including the fund and the managed accounts, disclaims beneficial ownership of the other’s shares and also disclaims being part of a group for purposes of Section 13(d) or 13(g).
Galera Therapeutics, Inc. President and CEO Mel Sorensen reported issuer dispositions on August 3, 2026 in connection with the Galera and Obsidian mergers. A stock option covering 30,000 Galera shares at an exercise price of $4.40 per share and 975 Galera common shares were disposed to Galera and converted into Parent common stock at a 0.7019-for-1 exchange ratio. The reported Galera option and share positions were reduced to zero, and all figures reflect a 1-for-200 reverse stock split completed on July 12, 2026.
Galera Therapeutics, Inc. director Kevin G. Lokay reported the disposition to the issuer of 240 stock options (rights to buy Galera common stock at an exercise price of 8.2000 per share) on August 3, 2026, in connection with Galera’s merger into a wholly owned subsidiary of Gazelle Parent, Inc.
Footnotes explain that, at the Galera merger effective time, in-the-money options were fully vested and converted into Gazelle Parent common stock using a 0.7019 Galera exchange ratio, while certain non‑in‑the‑money options were cancelled for no consideration, and that figures reflect a 1-for-200 reverse stock split completed July 12, 2026.
Galera Therapeutics director and 10% owner Nancy T. Chang reported equity restructuring transactions tied to preferred stock and a merger. On May 15, 2026, 661.309 shares of Series B Preferred Stock were mandatorily converted into 661,309 shares of common stock. After a 1-for-200 reverse stock split and the August 3, 2026 Galera merger, 47,434 common shares and a stock option over 480 shares were disposed to Galera in connection with their conversion into Parent common stock using a 0.7019 Galera Exchange Ratio and a net-exercise formula for in-the-money options.
Galera Therapeutics director Lawrence M. Alleva reported issuer-related dispositions of his remaining Galera securities tied to the completion of Galera’s mergers with Obsidian Therapeutics and Gazelle Parent, Inc. On August 3, 2026, he disposed of 240 Galera stock options (exercise price $8.20, expiring February 23, 2035) and the reported directly held and trust-held Galera common shares, which were transferred to the issuer and converted under the merger terms. Each Galera common share became the right to receive 0.7019 shares of Parent common stock, and Galera stock options with exercise prices below $15.62 were fully vested and converted into Parent shares, while higher-priced options were cancelled for no consideration. All reported figures reflect a 1-for-200 reverse stock split completed on July 12, 2026.
Galera Therapeutics, Inc. reports that Chief Accounting Officer Joel F. Sussman disposed of a stock option covering 10,000 shares of common stock at a $4.40 exercise price, leaving no Galera options reported as outstanding. The option figures were adjusted for Galera’s 1-for-200 reverse stock split and the transaction occurred in connection with the August 3, 2026 mergers, under which each Galera share became exchangeable for 0.7019 shares of Parent common stock and in‑the‑money options (exercise price below $15.62) were fully vested and settled in Parent stock, while out‑of‑the‑money options were cancelled without consideration.
Galera Therapeutics, Inc. director Michael R. Friedman reported restructuring-related equity changes tied to a preferred conversion and subsequent merger. On May 15, 2026, 2,989.399 shares of Series B Non-Voting Convertible Preferred Stock held indirectly through an Equity Trust Company Roth IRA were mandatorily converted into 2,989,399 shares of Galera common stock at a 1,000:1 Conversion Ratio. On August 3, 2026, following a 1-for-200 reverse stock split and completion of the Galera merger into a parent entity, 41,631 indirectly held Galera common shares and 480 in-the-money stock options with an $8.20 exercise price were disposed to the issuer and converted into rights to receive Parent common stock under the merger exchange formulas.